Stock listing

NASDAQ:GOSS Gossamer Bio, Inc. Stock

Home listing (NASDAQ) of Gossamer Bio, Inc.

Follow Gossamer Bio, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:GOSS

$10.72 USD -0.71 (-6.2%)

Close on Nov 20, 2026

Past year -95.7% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$10.65 – $11.60 USDNov 20, 2026
Volume
191,427 sharesNov 20, 2026
Market cap
$65.57M USDAt the close on Nov 20, 2026 · price × 6.12M shares outstanding
52-week range
$8.30 – $309.60 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$2.13M USDMedian day 195,600 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Gossamer Bio, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:GOSS · Home$10.72 USD-0.71 (-6.2%)191,427$11.02$11.60$10.65$11.43Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:GOSS · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$10.72-0.71-6.2%$11.02$11.60$10.65191,427
$11.43+0.39+3.5%$11.00$11.58$10.95242,628
$11.04+0.06+0.5%$10.85$11.45$10.22221,747
$10.98+0.01+0.1%$10.88$11.40$10.76207,137
$10.97-0.27-2.4%$11.19$11.40$10.60124,138
$11.24-0.45-3.8%$11.27$12.15$10.60188,954
$11.69+0.41+3.6%$9.76$11.94$9.71335,914
$11.28+0.635+6.0%$10.52$11.54$10.42100,202
$10.65+0.875+9.0%$10.02$11.58$9.545234,614
$9.77+0.35+3.7%$9.27$9.99$9.2782,378
$9.42-0.53-5.3%$9.77$9.77$8.91151,661
$9.95+0.67+7.2%$9.42$10.04$9.42115,809
$9.28-0.17-1.8%$9.38$9.68$8.80139,401
$9.45-0.93-9.0%$10.30$10.35$9.30190,762
$10.38-0.31-2.9%$10.56$10.74$10.19179,363
$10.690.000.0%$10.70$11.08$10.48105,481
$10.69+0.92+9.4%$9.61$10.88$9.45185,734
$9.77+0.62+6.8%$9.17$9.87$9.10137,818
$9.15-0.455-4.7%$9.61$9.61$8.72250,631
$9.605+0.145+1.5%$9.40$9.72$9.00144,773
$9.46-0.33-3.4%$9.73$9.957$9.34190,522
$9.79+0.21+2.2%$9.50$10.35$9.50218,879
$9.58+1.15+13.6%$8.41$9.58$8.30212,054
$8.43-0.34-3.9%$8.80$8.80$8.311179,473
$8.77-0.12-1.3%$8.88$8.995$8.51171,100
$8.89-0.015-0.2%$8.86$9.18$8.73197,700
$8.905-0.855-8.8%$9.59$9.641$8.77360,800
$9.76+0.48+5.2%$9.83$10.03$9.26478,000
$9.28-0.03-0.3%$9.54$9.54$8.99155,000
$9.31-0.57-5.8%$9.93$10.10$9.20289,900
$9.88-0.30-2.9%$10.02$10.28$9.657196,800
$10.18-0.60-5.6%$10.38$10.66$9.774280,600
$10.78+0.13+1.2%$10.77$10.93$10.50196,600
$10.65-0.06-0.6%$10.70$10.99$10.00390,900
$10.71-0.22-2.0%$11.19$11.19$10.19235,000
$10.93-0.92-7.8%$11.63$12.14$10.80351,800
$11.85+0.27+2.3%$11.53$12.46$11.16381,900
$11.58+0.06+0.5%$11.68$11.85$11.21384,000
$11.52+0.58+5.3%$10.46$11.85$10.33516,400
$10.94+0.01+0.1%$10.93$11.01$10.22426,600
$10.93-0.06-0.5%$10.76$11.68$10.75236,100
$10.99-0.70-6.0%$11.69$11.97$10.03453,800
$11.69+0.41+3.6%$11.48$12.31$11.35195,600
$11.28+0.55+5.1%$11.60$11.94$10.91258,800
$10.73-1.21-10.1%$12.00$12.49$10.67530,100
$11.94+0.98+8.9%$11.78$12.45$11.28267,700
$10.96+0.58+5.6%$10.77$11.24$9.961271,200
$10.38-0.32-3.0%$10.61$10.97$10.12220,300
$10.70-0.03-0.3%$10.95$11.08$10.07325,900
$10.73-0.63-5.5%$12.48$12.52$10.47472,300
$11.36-1.44-11.3%$12.24$12.56$11.20165,331
$12.80-1.60-11.1%$12.00$13.76$12.00296,181
$14.40+0.40+2.9%$13.76$14.72$13.441,081
$14.00-0.08-0.6%$13.76$14.48$13.441,265
$14.08+0.24+1.7%$13.84$14.08$13.12895
$13.84+0.48+3.6%$13.28$13.84$12.88900
$13.36-0.24-1.8%$13.20$13.84$12.801,144
$13.600.000.0%$13.68$14.40$13.441,586
$13.600.000.0%$13.76$13.84$13.121,238
$13.60-0.32-2.3%$14.08$14.24$13.042,413
$13.92-2.48-15.1%$15.92$16.16$13.604,555
$16.40+2.40+17.1%$14.40$17.12$13.447,431
$14.00+1.60+12.9%$12.00$14.96$11.687,361
$12.40-0.24-1.9%$13.60$13.60$11.6020,524
$12.64+0.08+0.6%$12.64$13.12$12.081,052

Splits

1 split · NASDAQ:GOSS · every price before a split is adjusted for it

DayRatioWhat
1-for-80Consolidation
Ticker
NASDAQ:GOSS
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Gossamer Bio, Inc. news

Gossamer Bio, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
21 in the last 12 months · 110 in all · newest Nov 10, 2026 · oldest 2019
Calls
11 calls with a replay · 11 with a transcript · latest May 18, 2026
Decks
10 decks · latest May 18, 2026

Where Gossamer Bio, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:GOSS · Home listing · This pageNASDAQUnited StatesUSD
gettex:4GBgettexGermanyEUR
LS Exchange:A2PCBSLS ExchangeGermanyEUR
Lang & Schwarz:A2PCBSLang & SchwarzGermanyEUR
BOATS:GOSSBOATSUnited StatesUSD
Tradegate:4GBTradegateGermanyEUR
Dusseldorf:4GBDusseldorfGermanyEUR
Frankfurt:4GBFrankfurtGermanyEUR
Munich:4GBMunichGermanyEUR
Stuttgart:4GBStuttgartGermanyEUR

Valuation

EV/sales 0.7× against a median of 28.6×: 2nd lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$55.23M USD
P/E
Loss
EV/sales
0.7×
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
99.7%
Operating margin
−140.0%
Net margin
−159.5%
Debt to equity
Negative equity
Beta vs S&P 500
1.56

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Gossamer Bio, Inc. · NASDAQ:GOSSUS$65.57MUS$55.23Mn/a0.7×n/an/a−159.5%n/a1.56
Cingulate Inc. · NASDAQ:CINGUS$67.48MUS$1.21Bn/an/an/a3.3×n/a56.0×1.41
Energenesis Biomedical Co., Ltd. · TWSE:6657US$67.20MUS$47.01Mn/a203×n/a3.1×n/a0.0×n/a
MediciNova, Inc. · NASDAQ:MNOVUS$67.11MUS$38.45Mn/a41.1×n/a1.6×n/a0.0×0.56
Dicot Pharma AB · OMXSTO:DICOTUS$66.64MUS$44.56Mn/an/an/a3.0×n/a0.0×n/a
Cardiff Oncology, Inc. · NASDAQ:CRDFUS$66.34MUS$32.82Mn/a58.7×n/a2.4×n/a0.0×1.32
Polaryx Therapeutics, Inc. · NASDAQ:PLYXUS$66.30MUS$57.86Mn/an/an/a8.7×n/a0.0×1.66
PMV Pharmaceuticals, Inc. · NASDAQ:PMVPUS$66.17M−US$36.25Mn/an/an/a1.2×n/a0.0×1.43
Tenaya Therapeutics, Inc. · NASDAQ:TNYAUS$65.32MUS$1.38Mn/a0.5×n/a1.2×n/a0.1×2.42
Atara Biotherapeutics, Inc. · NASDAQ:ATRAUS$64.49MUS$64.14Mn/a16.2×n/an/a−368.6%n/a1.43
AlzeCure Pharma AB · OMXSTO:ALZCURUS$63.92MUS$62.79M21.3×6.6×25.6×7.1×31.6%0.0×n/a
Median of the othersUS$66.32MUS$45.79M21.3×28.6×25.6×3.0×−168.5%0.0×1.43

Forecasts

3 strong buy · 1 buy · 3 hold · 1 sell · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.

Price target
83.40 USD · Analysts' mean
EPS, year to Dec 2026
-18.88 · 2 analysts
Revenue, year to Dec 2026
64.61M · 5 analysts

Team and board

Officers

OfficerRole
Faheem HasnainCo-Founder, Chairman, and Chief Executive Officer
Bryan GiraudoChief Operating Officer & Chief Financial Officer
Christian WaageExecutive Vice President, Technical Operations & General Counsel
Conor O’DonovanSenior Vice President, Regulatory Affairs
Deanna WeberExecutive Vice President, Human Resources
Jean-Marie BrueySenior Vice President, Translational Medicine and Research
Jeanine AnthonySenior Vice President, Marketing
Kelly DawsonSenior Vice President, Program Team Lead
Lou ChericoSenior Vice President, Finance & Treasury
Rob RoscignoSenior Vice President of Clinical Development, Pulmonary Vascular Disease
Bob SmithChief Commercial Officer
Caryn PetersonChief Development Officer

Board

DirectorRole
Faheem HasnainCo-Founder, Chairman, and Chief Executive Officer
Greg CiongoliDirector
John QuiselDirector
Russell J. CoxDirector
Sandra MilliganDirector
Skye DrynanDirector
Steven D. NathanDirector
Thomas DanielDirector

Events

Calls

CallWhenStatus
Gossamer Bio (NASDAQ:GOSS) Q1 2026 Earnings CallMon, May 18, 2026 · 8:00 AM ETReplay
Gossamer Bio (NASDAQ:GOSS) Q1 2025 Earnings CallThu, May 15, 2025 · 4:30 PM ETReplay
Gossamer Bio (NASDAQ:GOSS) Q4 2021 Earnings CallThu, Mar 03, 2022 · 4:30 PM ETReplay
Gossamer Bio (NASDAQ:GOSS) Q3 2021 Earnings CallMon, Nov 08, 2021 · 4:15 PM ETReplay
Gossamer Bio (NASDAQ:GOSS) Q2 2021 Earnings CallMon, Aug 09, 2021 · 4:30 PM ETReplay
Gossamer Bio (NASDAQ:GOSS) Q4 2020 Earnings CallThu, Feb 25, 2021 · 8:30 AM ETReplay
Gossamer Bio (NASDAQ:GOSS) Q3 2020 Earnings CallTue, Nov 10, 2020 · 4:30 PM ETReplay
Gossamer Bio (NASDAQ:GOSS) Q1 2020 Earnings CallFri, Jun 12, 2020 · 4:30 PM ETReplay
Gossamer Bio (NASDAQ:GOSS) Q3 2019 Earnings CallTue, Nov 12, 2019 · 4:30 PM ETReplay
Gossamer Bio (NASDAQ:GOSS) Q2 2019 Earnings CallThu, Aug 08, 2019 · 4:30 PM ETReplay
All 11 calls
CallWhenStatus
Gossamer Bio (NASDAQ:GOSS) Q1 2019 Earnings CallTue, May 14, 2019 · 8:30 AM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 10, 2026 · After close+3.6%
Q2 2026Aug 13, 2026 · After close−9.4%
Q1 2026May 15, 2026 · After close−43.2%
Q4 2025Mar 13, 2026−0.9%
Q3 2025Nov 5, 2025 · After close−2.5%
Q2 2025Aug 5, 2025 · After close−8.3%
Q1 2025May 15, 2025 · After close−0.9%
Q4 2024Mar 3, 2025 · Before open−4.1%
Q3 2024Nov 7, 2024 · After close−0.9%
Q2 2024Aug 12, 2024 · After close+3.8%
All 20 quarters
QuarterResultsShare move
Q1 2024May 7, 2024 · After close+3.1%
Q4 2023Mar 5, 2024 · Before open0.0%
Q3 2023Nov 9, 2023 · Before open−7.6%
Q2 2023Aug 8, 2023 · After close−1.6%
Q1 2023May 9, 2023 · After close+3.7%
Q4 2022Mar 17, 2023 · Before open−8.5%
Q3 2022Nov 3, 2022 · After close−0.8%
Q2 2022Aug 9, 2022 · Before open−0.4%
Q1 2022May 10, 2022 · After close+0.7%
Q4 2021Mar 3, 2022 · After close+6.2%

Open Events

Decks

DeckKindSlidesDate
Q1 2026 Earnings PresentationEarnings21 slidesMay 18, 2026
Technical Presentation (February 2026)Technical27 slidesFeb 23, 2026
Q1 2025 Earnings PresentationEarnings43 slidesMay 15, 2025
Corporate Update (July 2023)Corporate update33 slidesJul 20, 2023
Technical Presentation (December 2022)Technical39 slidesDec 6, 2022
ECCO'21 Virtual Congress (June 2021)Conference8 slidesJun 4, 2021
Technical Presentation (October 2020)Technical23 slidesOct 13, 2020
Investor Presentation (May 2019)Investor deck38 slidesMay 14, 2019
Technical Presentation (2019)Technical12 slides2019
Technical Presentation (2019)Technical11 slides2019

Open Decks

Financings

RaiseDate
Private placement of pre-funded warrants and FDA approval warrants
Announced: up to US$250M · US$0.1399 a share · Warrants at US$0.187 · Leerink Partners +1
Dealers: Leerink Partners (co-lead), Cantor (co-lead)
Buyers: EcoR1 Capital; 683 Capital Partners, LP; RA Capital Management; Coastlands Capital; Samsara BioCapital; Rock Springs Capital
Use of proceeds: Advance clinical development and potential commercialization of seralutinib in PAH and PH-ILD, general corporate purposes and working capital
Aug 21, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$16.00 a share on Feb 7, 2019.

Price
US$16.00 a share
Shares offered
17,250,000 shares of common stock
Offering size
US$276 million
Underwriters' option
Up to 2,587,500 more shares
Underwriters
BofA Merrill Lynch, SVB Leerink, Barclays, Evercore ISI · In the order on the cover
Shares delivered
On or about Feb 12, 2019

Steps

StepWhen
Draft sent to the SEC in confidenceOct 11, 2018
Filed publiclyDec 21, 2018
Amended twiceNewest Jan 30, 2019
Shares registered with an exchangeFeb 4, 2019
Declared effective by the SECFeb 7, 2019
Final prospectus, with the priceFeb 8, 2019

Open IPO · From the cover of the final prospectus (424B4) filed Feb 8, 2019

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue48.5M114.7M00000000
Cost of revenue1.00M4.15M4.38M4.43M5.17M4.27M3.09M297.0K00
Gross profit47.5M114.7M-4.38M-4.43M-5.17M-4.27M-3.09M-297.0K00
Research and development174.1M138.5M135.3M170.9M170.3M160.9M143.4M55.3M891.0K0
Selling, general and administrative37.6M36.1M38.5M47.6M45.8M49.7M39.1M44.1M262.0K83.0K
Operating income-170.7M-59.9M-183.8M-218.6M-216.1M-234.0M-186.1M-149.0M-6.65M-83.0K
Depreciation and amortization24.0K833.0K1.61M1.83M1.74M1.41M917.0K297.0K083.0K
EBITDA-170.7M-59.1M-182.2M-216.8M-214.4M-232.6M-185.2M-148.7M-6.65M0
Interest expense11.0M11.5M13.5M13.9M19.4M12.7M1.94M12.0K118.0K0
Income before tax-170.5M-55.6M-179.8M-229.4M-234.0M-243.4M-180.3M-147.0M6.77M-83.0K
Income tax-88.0K893.0K0015.1M8.22M000-83.0K
Net income-170.4M-56.5M-179.8M-229.4M-234.0M-243.4M-180.3M-147.0M-6.77M-83.0K
Earnings per share, basic-0.75-0.25-1.18-2.71-3.13-3.55-3.29-22.59-0.74-0.72
Earnings per share, diluted-0.75-0.25-1.18-2.71-3.13-3.55-3.29-22.59-0.74

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents37.7M46.1M32.1M112.0M183.4M486.1M135.0M105.2M315.0K60.0K
Short-term investments99.2M248.4M264.3M143.7M141.8M26.6M266.7M123.4M00
Receivables12.2M5.34M0200.0K200.0K1.50M500.0K
Inventory-136.0K365.0K-1.50M
Current assets167.6M309.9M306.5M261.9M331.8M522.3M409.3M232.0M445.0K60.0K
Property, plant and equipment64.0K10.0K1.65M3.98M5.32M5.53M5.42M3.19M
Total assets172.2M315.3M311.9M272.4M343.7M539.4M426.6M239.4M445.0K60.0K
Accounts payable5.96M2.32M5.53M1.46M3.24M7.51M956.0K2.18M97.0K40.0K
Current liabilities63.4M45.0M51.6M49.2M39.9M38.6M36.9M20.4M1.27M143.0K
Long-term debt198.5M0814.0K12.0M29.1M28.7M28.5M6.04M40.0K
Total debt202.9M012.4M23.6M29.1M28.7M28.5M6.04M40.0K
Total liabilities295.0M285.8M249.1M260.4M222.2M218.7M74.1M21.1M7.31M183.0K
Shareholders' equity-122.8M29.5M62.8M12.1M121.5M320.7M352.5M-120.1M-6.86M-123.0K
Shares outstanding2.92M226.6M225.4M94.4M75.8M73.9M61.6M8.05M75.5M114.5K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-171.3M-3.47M-159.2M-187.0M-188.9M-176.4M-144.8M-51.0M-5.75M20.0K
Capital spending-79.0K00-410.0K-1.55M-1.50M-2.97M-3.49M-3.49M-3.49M
Free cash flow-171.3M-3.47M-159.2M-187.4M-190.4M-177.9M-147.8M-54.5M-5.75M20.0K
Cash from investing156.4M29.0M-111.0M-1.03M-117.4M215.3M-147.1M-144.7M-144.7M-144.7M
Cash from financing6.42M-11.5M190.2M117.1M3.33M312.5M321.6M300.9M6.00M40.0K
Share buybacks629.0K444.0K122.9M3.33M117.6M293.4M303.0M
Change in cash-8.34M14.0M-79.9M-71.5M-303.2M351.5M29.7M105.1M255.0K0

Open Financials

Filings

FilingDateTypeFiled with
S-3 · Registration statementNov 16, 2026Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
8-K · Current reportNov 10, 2026ResultsSEC
10-Q · Quarterly reportNov 10, 2026Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 6, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 6, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 29, 2026Big-stake noticeSEC
8-K · Current reportOct 28, 2026Meeting outcomeSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 8, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedSep 28, 2026Big-stake noticeSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportSep 28, 2026Current reportSEC
4 · Change in ownershipSep 25, 2026Insider tradeSEC
4 · Change in ownershipSep 25, 2026Insider tradeSEC
4 · Change in ownershipSep 25, 2026Insider tradeSEC
4 · Change in ownershipSep 25, 2026Insider tradeSEC
4 · Change in ownershipSep 25, 2026Insider tradeSEC
4 · Change in ownershipSep 25, 2026Insider tradeSEC
4 · Change in ownershipSep 25, 2026Insider tradeSEC
8-K · Current reportSep 23, 2026Current reportSEC
3 · Initial statement of ownershipSep 22, 2026Insider tradeSEC
DEF 14A · Proxy statementSep 16, 2026Meeting noticeSEC
8-K · Current reportSep 16, 2026Management or board changeSEC
8-K · Current reportSep 11, 2026Current reportSEC
8-K · Current reportSep 9, 2026Current reportSEC
DSep 4, 2026Other filingsSEC
PRE 14A · Preliminary proxy statementSep 3, 2026Meeting noticeSEC
8-K · Current reportSep 3, 2026Current reportSEC
4 · Change in ownershipAug 26, 2026Insider tradeSEC
4 · Change in ownershipAug 26, 2026Insider tradeSEC
4 · Change in ownershipAug 26, 2026Insider tradeSEC
4 · Change in ownershipAug 26, 2026Insider tradeSEC
4 · Change in ownershipAug 26, 2026Insider tradeSEC
8-K · Current reportAug 26, 2026Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 24, 2026Big-stake noticeSEC
8-K · Current reportAug 21, 2026Material contractSEC
8-K · Current reportAug 13, 2026ResultsSEC
10-Q · Quarterly reportAug 13, 2026Quarterly reportSEC
SCHEDULE 13G · Big-stake noticeJul 29, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 29, 2026Big-stake noticeSEC
8-K · Current reportJul 27, 2026ResultsSEC
SCHEDULE 13D/A · Big-stake notice, amendedJul 24, 2026Big-stake noticeSEC
8-K · Current reportJul 14, 2026Management or board changeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJul 1, 2026Big-stake noticeSEC
8-K · Current reportJul 1, 2026Current reportSEC
8-K · Current reportJun 17, 2026Current reportSEC
SCHEDULE 13D · Big-stake noticeJun 11, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJun 11, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJun 11, 2026Big-stake noticeSEC
DEF 14A · Proxy statementJun 9, 2026Meeting noticeSEC
SCHEDULE 13G · Big-stake noticeJun 9, 2026Big-stake noticeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
8-K · Current reportJun 4, 2026Material contractSEC
8-K · Current reportJun 4, 2026Meeting outcomeSEC
8-K · Current reportJun 2, 2026Current reportSEC
PRE 14A · Preliminary proxy statementMay 18, 2026Meeting noticeSEC
DEFA14A · Additional proxy materialMay 18, 2026Meeting noticeSEC
8-K · Current reportMay 18, 2026ResultsSEC
10-Q · Quarterly reportMay 15, 2026Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 14, 2026Big-stake noticeSEC
ARS · Annual report to shareholdersApr 24, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 24, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 24, 2026Meeting noticeSEC
8-K · Current reportApr 9, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 27, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 24, 2026Big-stake noticeSEC
4 · Change in ownershipMar 20, 2026Insider tradeSEC
4 · Change in ownershipMar 20, 2026Insider tradeSEC
4 · Change in ownershipMar 20, 2026Insider tradeSEC
4 · Change in ownershipMar 20, 2026Insider tradeSEC
4 · Change in ownershipMar 20, 2026Insider tradeSEC
4 · Change in ownershipMar 20, 2026Insider tradeSEC
EFFECT · Notice that a registration is effectiveMar 19, 2026Other filingsSEC
POS AM · Amendment to an effective registrationMar 17, 2026Offer documentSEC
8-K · Current reportMar 17, 2026ResultsSEC
10-K · Annual reportMar 17, 2026Annual reportSEC
POSASRMar 17, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeMar 2, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedFeb 24, 2026Big-stake noticeSEC
8-K · Current reportFeb 23, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
S-3ASR · Registration statementJan 28, 2026Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 21, 2026Big-stake noticeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
8-K · Current reportNov 5, 2025ResultsSEC
10-Q · Quarterly reportNov 5, 2025Quarterly reportSEC
4 · Change in ownershipOct 2, 2025Insider tradeSEC
4 · Change in ownershipOct 2, 2025Insider tradeSEC
4 · Change in ownershipOct 2, 2025Insider tradeSEC
4 · Change in ownershipOct 2, 2025Insider tradeSEC
4 · Change in ownershipOct 2, 2025Insider tradeSEC
4 · Change in ownershipOct 2, 2025Insider tradeSEC
8-K · Current reportSep 25, 2025FinancingSEC
4 · Change in ownershipAug 20, 2025Insider tradeSEC
8-K · Current reportAug 5, 2025ResultsSEC
10-Q · Quarterly reportAug 5, 2025Quarterly reportSEC
SCHEDULE 13G · Big-stake noticeJul 29, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJul 17, 2025Big-stake noticeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
8-K · Current reportJun 25, 2025Management or board changeSEC
8-K · Current reportJun 16, 2025Current reportSEC
8-K · Current reportMay 15, 2025ResultsSEC
10-Q · Quarterly reportMay 15, 2025Quarterly reportSEC
ARS · Annual report to shareholdersApr 29, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2025Meeting noticeSEC
S-8 · Registration statement for employee plansMar 13, 2025Offer documentSEC
8-K · Current reportMar 13, 2025ResultsSEC
10-K · Annual reportMar 13, 2025Annual reportSEC
4 · Change in ownershipMar 6, 2025Insider tradeSEC
4 · Change in ownershipMar 6, 2025Insider tradeSEC
4 · Change in ownershipMar 6, 2025Insider tradeSEC
4 · Change in ownershipMar 6, 2025Insider tradeSEC
4 · Change in ownershipMar 6, 2025Insider tradeSEC
4 · Change in ownershipMar 6, 2025Insider tradeSEC
8-K · Current reportFeb 19, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 5, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 30, 2025Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
8-K · Current reportNov 7, 2024ResultsSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC
8-K · Current reportSep 13, 2024Current reportSEC
8-K · Current reportAug 12, 2024ResultsSEC
10-Q · Quarterly reportAug 12, 2024Quarterly reportSEC
SC 13G/A · Big-stake notice, amendedAug 2, 2024Big-stake noticeSEC
8-K · Current reportJul 18, 2024Current reportSEC
4 · Change in ownershipJun 25, 2024Insider tradeSEC
4 · Change in ownershipJun 24, 2024Insider tradeSEC
4 · Change in ownershipJun 20, 2024Insider tradeSEC
4 · Change in ownershipJun 20, 2024Insider tradeSEC
8-K · Current reportJun 10, 2024Meeting outcomeSEC
4 · Change in ownershipJun 6, 2024Insider tradeSEC
4 · Change in ownershipJun 6, 2024Insider tradeSEC
4 · Change in ownershipJun 6, 2024Insider tradeSEC
4 · Change in ownershipJun 6, 2024Insider tradeSEC
8-K · Current reportMay 24, 2024Current reportSEC
8-K · Current reportMay 7, 2024ResultsSEC
10-Q · Quarterly reportMay 7, 2024Quarterly reportSEC
8-K · Current reportMay 6, 2024Material contractSEC
ARS · Annual report to shareholdersApr 26, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 24, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 24, 2024Meeting noticeSEC
4 · Change in ownershipMar 28, 2024Insider tradeSEC
4 · Change in ownershipMar 28, 2024Insider tradeSEC
4 · Change in ownershipMar 28, 2024Insider tradeSEC
4 · Change in ownershipMar 19, 2024Insider tradeSEC
4 · Change in ownershipMar 19, 2024Insider tradeSEC
4 · Change in ownershipMar 12, 2024Insider tradeSEC
4 · Change in ownershipMar 12, 2024Insider tradeSEC
3 · Initial statement of ownershipMar 12, 2024Insider tradeSEC
3 · Initial statement of ownershipMar 12, 2024Insider tradeSEC
8-K · Current reportMar 12, 2024Management or board changeSEC
S-8 · Registration statement for employee plansMar 5, 2024Offer documentSEC
10-K · Annual reportMar 5, 2024Annual reportSEC
8-K · Current reportMar 5, 2024ResultsSEC
8-K · Current reportMar 4, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 9, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeJan 11, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedJan 11, 2024Big-stake noticeSEC
4 · Change in ownershipJan 4, 2024Insider tradeSEC
4 · Change in ownershipJan 4, 2024Insider tradeSEC
4 · Change in ownershipJan 4, 2024Insider tradeSEC
4 · Change in ownershipJan 4, 2024Insider tradeSEC
4 · Change in ownershipJan 4, 2024Insider tradeSEC
4 · Change in ownershipDec 5, 2023Insider tradeSEC
3 · Initial statement of ownershipDec 5, 2023Insider tradeSEC
4 · Change in ownershipNov 29, 2023Insider tradeSEC
3 · Initial statement of ownershipNov 29, 2023Insider tradeSEC
8-K · Current reportNov 29, 2023Management or board changeSEC
8-K · Current reportNov 27, 2023Management or board changeSEC
4 · Change in ownershipNov 22, 2023Insider tradeSEC
4 · Change in ownershipNov 22, 2023Insider tradeSEC
4 · Change in ownershipNov 22, 2023Insider tradeSEC
4 · Change in ownershipNov 22, 2023Insider tradeSEC
4 · Change in ownershipNov 22, 2023Insider tradeSEC
4 · Change in ownershipNov 17, 2023Insider tradeSEC
4 · Change in ownershipNov 14, 2023Insider tradeSEC
10-Q · Quarterly reportNov 9, 2023Quarterly reportSEC
8-K · Current reportNov 9, 2023ResultsSEC
8-K · Current reportOct 20, 2023Current reportSEC
8-K · Current reportSep 7, 2023Management or board changeSEC

This page holds 200 of 490 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Gossamer Bio, Inc.’s releases · as of Nov 7, 2026

Common shares
6,116,390
Fully diluted
6,116,390

Fully diluted

LineSharesAs of
Common shares6,116,390Nov 7, 2026

Share count over time

CountShares
Nov 7, 20266,116,390
Sep 11, 2026
Sep 9, 2026

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Octagon Capital Advisors LP96,8751.6%US$1.15MSep 30, 2026
NEA Management Company, LLC12,5000.20%US$148KSep 30, 2026
IFP Advisors, Inc98<0.01%US$14Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund6.91M113.0%US$1.14MJun 30, 2026
Vanguard Extended Market Index Fund2.24M36.7%US$369KJun 30, 2026
iShares Biotechnology ETF1.5M24.5%US$247KJun 30, 2026
Fidelity Extended Market Index Fund1.15M18.8%US$266KMay 31, 2026
Schwab U.S. Small-Cap ETF987K16.1%US$228KMay 31, 2026
Vanguard Russell 2000 Index Fund977K16.0%US$226KMay 31, 2026
Invesco RAFI US 1500 Small-Mid ETF556K9.1%US$94,309Jul 31, 2026
Vanguard Health Care Index Fund542K8.9%US$125KMay 31, 2026
Fidelity Total Market Index Fund381K6.2%US$88,004May 31, 2026
BlackRock Health Sciences Opportunities Portfolio365K6.0%US$84,324May 29, 2026
All 47 holders
HolderSharesOf the companyValueAs of
Fidelity Series Total Market Index Fund300K4.9%US$69,367May 31, 2026
iShares Core S&P Total U.S. Stock Market ETF294K4.8%US$48,394Jun 30, 2026
Goldman Sachs Absolute Return Tracker Fund267K4.4%US$43,989Jun 30, 2026
Eventide Small Cap ETF205K3.3%US$34,671Jul 31, 2026
Vanguard Russell 2000 Growth Index Fund180K2.9%US$41,621May 31, 2026
Vanguard Balanced Index Fund154K2.5%US$25,417Jun 30, 2026
Fidelity Nasdaq Composite Index Fund150K2.4%US$34,563May 31, 2026
PACE Small/Medium Co Growth Equity Investments145K2.4%US$24,646Jul 31, 2026
Vanguard Institutional Total Stock Market Index Fund107K1.8%US$17,673Jun 30, 2026
Fidelity ZERO Total Market Index Fund99,9761.6%US$16,946Jul 31, 2026
Fidelity ZERO Extended Market Index Fund74,7461.2%US$12,669Jul 31, 2026
Small Cap Index Fund73,0971.2%US$16,878May 31, 2026
Blackstone Alternative Multi-Strategy Fund59,4000.97%US$9,777Jun 30, 2026
Invesco Russell 2000 Dynamic Multifactor ETF57,1260.93%US$13,190May 31, 2026
Diversified Equity Alpha Master Portfolio50,8200.83%US$8,365Jun 30, 2026
Siit Small Cap Fund47,3300.77%US$10,929May 31, 2026
Bridge Builder Small/Mid Cap Growth Fund36,5240.60%US$6,012Jun 30, 2026
Fidelity Flex Small Cap Index Fund35,8390.59%US$6,075Jul 31, 2026
U.S. Small Cap Equity Fund30,0150.49%US$5,088Jul 31, 2026
Siit Extended Market Index Fund28,3000.46%US$6,534May 31, 2026
Health Sciences Portfolio21,8340.36%US$3,594Jun 30, 2026
Vanguard Russell 3000 Index Fund16,6830.27%US$3,852May 31, 2026
VIP Extended Market Index Portfolio13,3870.22%US$2,204Jun 30, 2026
Invesco Nasdaq Biotechnology ETF12,2080.20%US$2,819May 31, 2026
Strategic Equity Allocation Trust10,5530.17%US$1,737Jun 30, 2026
U.S. Small Cap Equity Fund9,0570.15%US$1,491Jun 30, 2026
ProShares Russell 2000 High Income ETF9,0430.15%US$2,088May 31, 2026
ProShares Ultra Nasdaq Biotechnology8,5550.14%US$1,975May 31, 2026
Morgan Stanley Pathway Small-Mid Cap Equity ETF7,2220.12%US$1,668May 31, 2026
ProShares UltraPro Russell20007,1460.12%US$1,650May 31, 2026
ProShares Ultra Russell20007,0720.12%US$1,633May 31, 2026
Destinations Small-Mid Cap Equity Fund6,1170.10%US$1,412May 31, 2026
Total Stock Market Index Trust5,0670.08%US$834Jun 30, 2026
VIP Total Market Index Portfolio4,9010.08%US$807Jun 30, 2026
Knights of Columbus U.S. ALL CAP INDEX FUND1,2900.02%US$219Jul 31, 2026
ProShares Hedge Replication ETF180<0.01%US$42May 31, 2026
ProShares Russell 2000 Dynamic Buffer ETF57<0.01%US$13May 31, 2026

Big stakes

StakeStakeSharesDateFiling
683 Capital Management, LLC9.99%49.9MJun 4, 2026Schedule 13G
Context Capital Management, LLC9.90%48.8MJun 4, 2026Schedule 13G
D. E. Shaw & Co., L.L.C.6.00%29.1MAug 20, 2026Schedule 13D
Opaleye Management Inc.5.10%24.9MJul 22, 2026Schedule 13G
Growth Equity Opportunities 18 VGE, LLC1.70%4.07MFeb 23, 2026Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Faheem Hasnain
Other companies: Aspen Neuroscience, Inc. (Aspen Executive Chairman · Since at least Nov 2, 2026); Kura Oncology, Inc. (Lead Independent Director · Since at least Apr 23, 2015); Nuvation Bio Inc. (Director · Jun 30, 2020 – Feb 10, 2021 · Past); Tocagen Inc (Director · Apr 12, 2017 – Oct 4, 2019 · Past); Immunic, Inc. (Director · Aug 11, 2016 – Sep 13, 2018 · Past); Ambit Biosciences Corp (Director · May 15, 2013 – Nov 10, 2014 · Past); Receptos Inc (President & CEO, Director · May 8, 2013 – Aug 25, 2015 · Past); Somaxon Pharmaceuticals Inc (Director · Sep 16, 2010 – Dec 31, 2012 · Past); Facet Biotech Corp (President & CEO, Director · Dec 9, 2008 – Apr 21, 2010 · Past); PDL BioPharma Inc (President & CEO, Director · Oct 1, 2008 – Oct 1, 2008 · Past)
Co-Founder, Chairman, and Chief Executive Officer · Since at least Feb 7, 2019
Kristina Burow
Other companies: Kardigan, Inc. (Director · Since at least Jun 22, 2026); Metsera, Inc. (Director · Since at least Jan 30, 2025); Boundless Bio, Inc. (Director · Since at least Mar 27, 2024); Neumora Therapeutics, Inc. (Director · Since at least Sep 14, 2023); Scholar Rock Holding Corporation (Director · Since at least May 23, 2018); Metacrine Inc (Director · Sep 15, 2020 – May 24, 2021 · Past); Beam Therapeutics Inc. (Director · Feb 5, 2020 – Jun 6, 2023 · Past); Vir Biotechnology, Inc. (Director · Oct 10, 2019 – May 21, 2020 · Past); Unity Biotechnology Inc (Director · May 2, 2018 – Jun 24, 2021 · Past); Receptos Inc (Director · Aug 25, 2015 – Aug 25, 2015 · Past)
Director · Feb 7, 2019 – Jun 8, 2023 · Past
Sheila Gujrathi
Other companies: Bolt Biotherapeutics, Inc. (Chief Strategy Officer · Since at least Oct 23, 2026); BlossomHill Therapeutics, Inc. (Director · Since at least Aug 6, 2026); Processa Pharmaceuticals, Inc. (Director · Since at least Jul 28, 2026); Ventyx Biosciences Inc (Director · Since at least Oct 20, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Turning Point Therapeutics Inc (Director · Apr 16, 2019 – Jun 15, 2020 · Past); Five Prime Therapeutics Inc (Director · Dec 2, 2015 – May 10, 2018 · Past); Receptos Inc (Chief Medical Officer · May 8, 2013 – Aug 25, 2015 · Past)
President & CEO, Director · Feb 7, 2019 – Feb 14, 2020 · Past
Otello Stampacchia
Other companies: Windward Bio Group AG (Founder & Managing Director, Omega Fund Management, LLC · Since at least Nov 16, 2026); ImageneBio, Inc. (Director · Since at least Mar 25, 2021); Omega Alpha SPAC (Chief Executive Officer, Director · Jan 6, 2021 – Jan 11, 2021 · Past); Kronos Bio Inc (Director · Oct 8, 2020 – Jun 22, 2022 · Past); Morphic Holding Inc (Director · Jun 26, 2019 – Apr 29, 2021 · Past); Replimune Group, Inc. (Director · Jul 19, 2018 – Nov 19, 2021 · Past)
Director · Feb 7, 2019 – Sep 10, 2019 · Past
Jakob Dupont
Other companies: Bolt Biotherapeutics, Inc. (Director · Since at least Sep 3, 2024); Pyxis Oncology, Inc. (Director · Since at least Aug 23, 2023); Apexigen Inc. (Director · Jul 29, 2022 – Aug 23, 2023 · Past); Atara Biotherapeutics, Inc. (EVP, Head of R&D · May 14, 2020 – Mar 2, 2023 · Past); OncoMed Pharmaceuticals Inc (SVP & Chief Medical Officer · Jul 17, 2013 – Oct 9, 2016 · Past)
Chief Medical Officer · Feb 7, 2019 – Feb 14, 2020 · Past
Thomas Daniel
Other companies: Dianthus Therapeutics, Inc. (Director · Jun 20, 2018 – Jun 28, 2022 · Past); Larimar Therapeutics, Inc. (Director · Mar 3, 2016 – May 12, 2021 · Past); Juno Therapeutics Inc (Director · Aug 11, 2015 – Mar 5, 2018 · Past); Epizyme Inc (Director · May 30, 2013 – May 30, 2013 · Past); Celgene Corporation (see remarks · Feb 15, 2012 – Dec 31, 2015 · Past)
Director · Since at least Feb 7, 2019
Greg Ciongoli
Other companies: Theravance Biopharma, Inc. (Director · Since at least Nov 4, 2026); Regenxbio Inc. (Independent Board Member · Since at least Aug 25, 2026); Zymeworks Inc. (Director · Since at least Jan 12, 2026); Atara Biotherapeutics, Inc. (Director · Since at least Sep 3, 2025)
Director · Since at least Sep 16, 2026
Renée Galá
Other companies: DexCom, Inc. (Director · Since at least Mar 6, 2025); Jazz Pharmaceuticals plc (President & CEO, Director · Since at least Mar 16, 2020); Corcept Therapeutics Incorporated (Director · Mar 6, 2018 – Aug 20, 2018 · Past); Theravance Biopharma, Inc. (SVP, Chief Financial Officer · Nov 20, 2017 – Nov 20, 2018 · Past)
Director · Feb 7, 2019 – Jun 8, 2023 · Past
Gregory Austin Ciongoli
Other companies: Regenxbio Inc. (Director · Since at least Aug 25, 2026); Zymeworks Inc. (Director · Since at least Aug 10, 2025); Atara Biotherapeutics, Inc. (Director · Since at least Sep 3, 2024)
Director · Since at least Sep 16, 2026
Russell J. Cox
Other companies: Immunic, Inc. (Chief Executive Officer, Director · Jan 3, 2018 – Jan 11, 2019 · Past); Spyre Therapeutics, Inc. (Director · Apr 6, 2016 – Jun 22, 2023 · Past); Jazz Pharmaceuticals plc (EVP & COO · Feb 8, 2011 – Dec 11, 2017 · Past)
Director · Since at least Feb 7, 2019
All 31 people
PersonSeat
Sandra Milligan
Other companies: Spyre Therapeutics, Inc. (Chair of the Nominating and Corporate Governance Committee · Since at least May 14, 2024); Aspira Women's Health Inc. (Interim CEO & President · Apr 1, 2024 – Dec 31, 2024 · Past); Organon & Co. (Head of Research & Development · Jun 2, 2021 – May 4, 2023 · Past)
Director · Since at least Jun 10, 2021
John Quisel
Other companies: Disc Medicine, Inc. (Chief Executive Officer · Since at least Dec 29, 2022); Acceleron Pharma Inc (EVP, Chief Business Officer · Sep 18, 2013 – Jan 2, 2020 · Past)
Director · Since at least Nov 28, 2023
Bryan Giraudo
Other companies: Protagonist Therapeutics, Inc. (Director · Since at least May 15, 2018)
Chief Operating Officer & Chief Financial Officer · Since at least Feb 7, 2019
Caryn Peterson
Other companies: Aspen Neuroscience, Inc. (Chief Development Officer, Gossamer · Since at least Nov 5, 2026)
Chief Development Officer · Since at least Apr 16, 2021
Christian Waage
Other companies: Heron Therapeutics, Inc. (Director · Since at least Nov 5, 2026)
Executive Vice President, Technical Operations & General Counsel · Since at least Nov 5, 2026
Luisa Salter-Cid
Other companies: Jounce Therapeutics Inc (Director · Feb 10, 2021 – May 3, 2023 · Past)
Chief Scientific Officer · Feb 7, 2019 – Mar 23, 2021 · Past
Waage Christian
Other companies: Heron Therapeutics, Inc. (Director · Since at least Jan 19, 2024)
EVP, Tech Ops and Admin · Since at least Nov 20, 2023
Bob SmithChief Commercial Officer · Since at least Nov 4, 2026
Conor O’DonovanSenior Vice President, Regulatory Affairs · Since at least Nov 5, 2026
Deanna WeberExecutive Vice President, Human Resources · Since at least Nov 5, 2026
Jeanine AnthonySenior Vice President, Marketing · Since at least Nov 5, 2026
Jean-Marie BrueySenior Vice President, Translational Medicine and Research · Since at least Nov 5, 2026
Kelly DawsonSenior Vice President, Program Team Lead · Since at least Nov 5, 2026
Laura CarterChief Scientific Officer · May 4, 2022 – Mar 20, 2023 · Past
Lou ChericoSenior Vice President, Finance & Treasury · Since at least Nov 5, 2026
Richard ArandaChief Medical Officer · Since at least Jun 21, 2021
Robert Paul Smith JrChief Commercial Officer · Since at least Dec 4, 2023
Rob RoscignoSenior Vice President of Clinical Development, Pulmonary Vascular Disease · Since at least Nov 5, 2026
Skye DrynanDirector · Since at least Mar 11, 2024
Steven D NathanDirector · Since at least Mar 11, 2024
Steven D. NathanDirector · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about Gossamer Bio, Inc.